Skip to main content
Fig. 7 | Journal of Experimental & Clinical Cancer Research

Fig. 7

From: Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia

Fig. 7

Tigecycline has no obvious inhibitory effect on normal cells. (a) Death of normal bone marrow mononuclear cells exposed to tigecycline in different time points were measured by flow cytometry. (b) Western blot analysis of cleaved caspase-3 protein level in normal cells. (c) Effect of tigecycline on the oxygen consumption rate (OCR) curves and values for CML cells and normal cells. (d) Analyses of the glycolysis capacity of leukemic and normal cells were performed before and after stimulation with tigecycline. (e) The mitochondrial membrane potentials of leukemic and normal cells before and after treatment with tigecycline. (f) Mitochondrial mass of normal cells and CML cells was measured by incubating the cells with MitoTracker® Green FM dye. (g) Mitochondrial DNA (mtDNA) copy number was analyzed by QPCR. *P < 0.05

Back to article page